Announcements Trials
Browse Landscape

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 2

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Recurrence 1

Interventions

Carboplatin 1174Cisplatin 891Pemetrexed 847pembrolizumab 626Paclitaxel 609Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 264Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Microbiota × Thoracic × Clear all
NCT06221800 2026-02-05

Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects

University of California, Irvine

Recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04636775 2023-12-11

Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

University of Kansas Medical Center

Unknown
46 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡